---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-042061"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2023-08-31T23:59:59+00:00"
generated_at: "2026-06-11T01:39:30.594981+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics appoints Dorothy J. Clarke as director effective August 28, 2023

## Summary
- Ms. Clarke served as VP, Health Care Compliance R&D at Johnson & Johnson until November 2022.
- Board determined Clarke is independent under Nasdaq rules; standard non-employee director comp applies.
- No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K exist.

## SEC filing metadata
- accession: 0001140361-23-042061
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2023-08-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036123042061/0001140361-23-042061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036123042061/brhc20058268_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-042061
- JSON: https://secwatch.observer/filing/0001140361-23-042061.json
- Plain text: https://secwatch.observer/filing/0001140361-23-042061.txt

## Key facts
- Executive change
  Dorothy J. Clarke was appointed as director at Ernexa Therapeutics Inc..
  - Action: appointed
  - Role: director
  source text: On August 28, 2023, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Ms. Dorothy J. Clarke as a director, effective on August 28, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123042061/0001140361-23-042061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.